Navigation Links
Inverness Medical Innovations Announces Third Quarter 2008 Results
Date:10/29/2008

d share calculation for the nine months

ended September 30, 2008, on an adjusted cash basis, includes the

add back of interest expense related to the convertible debt of $2.1

million resulting in net income available to common stockholders of

$108.6 million. Potential dilutive shares consisting of 5,479,000

common stock equivalent shares from the potential conversion of

Series B convertible preferred stock for the nine months ended

September 30, 2008 were not used in the calculation of diluted net

income per common share, on an adjusted cash basis, because

inclusion thereof would be antidilutive.

(m) Included in the weighted average diluted common shares for the

calculation of net income per common share for the nine months ended

September 30, 2007, on an adjusted cash basis, are dilutive shares

consisting of 2,283,000 common stock equivalent shares from the

potential exercise of stock options and warrants. Potential

dilutive shares consisting of 1,471,000 common stock equivalent

shares from the potential conversion of convertible debt securities

for the nine months ended September 30, 2007 were not used in the

calculation of diluted net income per common share, on an adjusted

cash basis, because inclusion thereof would be antidilutive.

Inverness Medical Innovations, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in $000s)

September 30, December 31,

2008 2007

(unaudited)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $154,170 $414,732


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
2. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
3. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
4. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
5. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
6. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
7. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
8. Inverness Medical Innovations Announces Second Quarter 2008 Results
9. Inverness Medical Innovations to Present at Jefferies 2nd Annual Healthcare Conference held on June 25, 2008
10. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
11. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PA (PRWEB) November 25, 2014 The ... of its official conference and exposition mobile app, ... for free download in the App Store for iOS ... a valuable resource tool before, during and after the ... containing details on exhibiting companies, technical sessions, Conferee Networking ...
(Date:11/26/2014)... 2014 CURE™ magazine will ... December 5, 2014, in San Francisco prior to the ... event will honor clinicians, caregivers, and advocates who have ... (MPNs). , Special guest speaker Charles Esten, from ... journey at the reception. Over a decade ago, ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 /PRNewswrie/ -- Theravalues ... per il mercato europeo in occasione di Hi Europe ... ). Si tratta della curcumina con ... tecnologia amorfa (senza cristalli) e ingredienti approvati dalle norme ... presente nella spezia della pianta curcumina ( Curcuma longa ...
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
Breaking Biology Technology:Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE Amex: SVA ... it will host a conference call on Wednesday, August 19, ... financial results for the period,ended June 30, 2009 and provide ... To access the conference call, please dial 1-877-407-4018 (USA) ...
... Peripheral Drug-Eluting Stent Now Available in Europe , ... (NASDAQ: ANPI , TSX: ANP) today announced ... reported CE Mark approval and limited commercial launch of ... approval represents a global landmark in bringing drug-eluting stent ...
... , , , ... Systems today announced that BD Biosciences, a segment of BD ... its Search and Pathway Navigation technologies into its new website. ... Biosciences will enable its research customers to quickly and easily ...
Cached Biology Technology:Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results 2Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent 2Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent 3Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent 4Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent 5Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent 6Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent 7Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent 8Ingenuity's Technology Powers BD Cell Pathways Tool on New BD Biosciences Website 2
(Date:11/7/2014)... , November 6, 2014 Leading Biometric ... better mobile security revolutionizing online transactions.  Companies in focus today ... Ltd. (NYSE: BABA ), Google Inc. (NASDAQ: ... eBay Inc. (NASDAQ: EBAY ) and MasterCard Inc. ... and NXTDW), a biometric authentication company focused on the ...
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/4/2014)... of Utah engineers developed the first room-temperature fuel cell ... without needing to ignite the fuel. These new fuel ... power and sensors. , A study of the new ... journal ACS Catalysis . , Fuel cells convert ... fuel and an oxygen-rich source such as air. If ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Jet-fueled electricity at room temperature 2
... Institutes have discovered that environmental factors critically influence the ... cell--that is derived from adult skin cells. This discovery ... also advancing science closer to stem cell-based therapies to ... Senior Investigator Shinya Yamanaka, MD, PhD, have for the ...
... 4 July 2012 The Raffles Museum of Biodiversity ... Faculty of Science today launched a new book titled ... the precious biodiversity found in Singapore,s rainforests and the ... RMBR also introduced the "Digital Nature Archive of Singapore" ...
... out that the olfactory system in hermit crabs is ... While flies have a very sensitive sense of smell ... the air, crabs recognize only a few odors, such ... seawater. Humidity significantly enhanced electrical signals induced in their ...
Cached Biology News:Gladstone scientists identify critical process in stem cell development 2Gladstone scientists identify critical process in stem cell development 3NUS launches new book on Singapore's rainforests and new free digital nature archive 2Humidity increases odor perception in terrestrial hermit crabs 2Humidity increases odor perception in terrestrial hermit crabs 3
...
DONOR BOVINE SERUM AND PLASMA...
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: